| Primary |
| Multiple Sclerosis |
49.4% |
| Product Used For Unknown Indication |
18.3% |
| Relapsing-remitting Multiple Sclerosis |
16.2% |
| Multiple Sclerosis Relapse |
2.1% |
| Prophylaxis |
1.7% |
| Back Pain |
1.3% |
| Depression |
1.3% |
| Hypertension |
1.3% |
| Influenza Like Illness |
1.3% |
| Pain |
1.3% |
| Premedication |
1.3% |
| Fatigue |
0.9% |
| Type 2 Diabetes Mellitus |
0.9% |
| Amyotrophic Lateral Sclerosis |
0.4% |
| Anxiety |
0.4% |
| Arthritis |
0.4% |
| Blood Cholesterol Increased |
0.4% |
| Bundle Branch Block Right |
0.4% |
| Condition Aggravated |
0.4% |
| Constipation |
0.4% |
|
| Multiple Sclerosis Relapse |
15.5% |
| Drug Dose Omission |
12.7% |
| Secondary Progressive Multiple Sclerosis |
11.3% |
| Underdose |
7.0% |
| Injection Site Haemorrhage |
5.6% |
| Anxiety |
4.2% |
| Contusion |
4.2% |
| Influenza Like Illness |
4.2% |
| Pain |
4.2% |
| Acute Promyelocytic Leukaemia |
2.8% |
| Atrioventricular Block Complete |
2.8% |
| Autoimmune Disorder |
2.8% |
| Fall |
2.8% |
| Fatigue |
2.8% |
| Focal Segmental Glomerulosclerosis |
2.8% |
| Haemolytic Uraemic Syndrome |
2.8% |
| Injection Site Haematoma |
2.8% |
| Memory Impairment |
2.8% |
| Nephrotic Syndrome |
2.8% |
| Tremor |
2.8% |
|
| Secondary |
| Multiple Sclerosis |
52.3% |
| Drug Use For Unknown Indication |
7.5% |
| Relapsing-remitting Multiple Sclerosis |
6.7% |
| Product Used For Unknown Indication |
5.9% |
| Depression |
3.8% |
| Multiple Sclerosis Relapse |
3.2% |
| Hypertension |
3.0% |
| Premedication |
3.0% |
| Anxiety |
2.4% |
| Fatigue |
1.9% |
| Pain |
1.9% |
| Insomnia |
1.1% |
| Muscle Spasms |
1.1% |
| Palpitations |
1.1% |
| Supplementation Therapy |
1.1% |
| Urinary Tract Infection |
1.1% |
| Hepatic Cirrhosis |
0.8% |
| Psychotherapy |
0.8% |
| Sleep Disorder |
0.8% |
| Bipolar Disorder |
0.5% |
|
| Drug Dose Omission |
16.5% |
| Myocardial Infarction |
8.9% |
| Injection Site Haemorrhage |
7.6% |
| Underdose |
6.3% |
| Aggression |
5.1% |
| Completed Suicide |
5.1% |
| Influenza Like Illness |
5.1% |
| Multiple Sclerosis Relapse |
5.1% |
| Drug Ineffective |
3.8% |
| Drug Withdrawal Syndrome |
3.8% |
| Dyspnoea |
3.8% |
| Fall |
3.8% |
| Memory Impairment |
3.8% |
| Pain |
3.8% |
| Pyrexia |
3.8% |
| Sarcoidosis |
3.8% |
| Anxiety |
2.5% |
| Convulsion |
2.5% |
| Coordination Abnormal |
2.5% |
| Death |
2.5% |
|
| Concomitant |
| Multiple Sclerosis |
55.3% |
| Product Used For Unknown Indication |
7.7% |
| Pain |
5.9% |
| Progressive Multiple Sclerosis |
5.6% |
| Depression |
4.0% |
| Smoking Cessation Therapy |
2.4% |
| Neuralgia |
2.1% |
| Convulsion |
1.6% |
| Diabetes Mellitus |
1.6% |
| Drug Use For Unknown Indication |
1.6% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Urinary Incontinence |
1.6% |
| Anxiety |
1.3% |
| Fatigue |
1.3% |
| Hypertension |
1.1% |
| Influenza Like Illness |
1.1% |
| Insomnia |
1.1% |
| Irritable Bowel Syndrome |
1.1% |
| Mobility Decreased |
1.1% |
| Muscle Spasticity |
1.1% |
|
| Multiple Sclerosis Relapse |
13.5% |
| Breast Dysplasia |
8.1% |
| Weight Increased |
8.1% |
| Pyrexia |
6.8% |
| Rash |
6.8% |
| Drug Ineffective |
5.4% |
| Breast Cancer |
4.1% |
| Depression |
4.1% |
| Malaise |
4.1% |
| Multiple Sclerosis |
4.1% |
| Nuclear Magnetic Resonance Imaging Abnormal |
4.1% |
| Pain |
4.1% |
| Product Taste Abnormal |
4.1% |
| Sinusitis |
4.1% |
| Tremor |
4.1% |
| Visual Impairment |
4.1% |
| Abdominal Pain Upper |
2.7% |
| Aphasia |
2.7% |
| Breast Operation |
2.7% |
| Cardiac Failure Congestive |
2.7% |
|
